[A22-123] Daridorexant (chronic insomnia) - Benefit assessment according to § 35a SGB V
Last updated 12.05.2023
Project no.:
A22-123
Commission:
Commission awarded on 16.11.2022 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Head and nerves
Adults with insomnia, characterized by symptoms present for at least 3 months, who have not responded to cognitive behavioural therapy or for whom this type of therapy is not suitable or not feasible
Added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A23-22 | Daridorexant (insomnia) – Addendum to Commission A22-123 | Commission completed |
| A24-24 | Daridorexant (insomnia) – Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2023-05-12 A G-BA decision was published.